XML 43 R31.htm IDEA: XBRL DOCUMENT v3.22.4

Concentrations of Credit Risk and Current Expected Credit Losses (Tables)

12 Months Ended

Dec. 31, 2022

Risks and Uncertainties [Abstract]

Schedule of concentration of credit risk related to specialty pharmacy customers

The concentration of credit risk related to our JAKAFI, PEMAZYRE and OPZELURA product revenues is as follows:

			Percentage of Total Net Product Revenues for the Years Ended, December 31,
			2022						2021						2020
Customer A			19		%				18		%				20		%
Customer B			11		%				12		%				13		%
Customer C			18		%				18		%				17		%
Customer D			5		%				9		%				11		%
Customer E			10		%				11		%				10		%
Customer F			14		%				8		%				5		%

X

- Definition

Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark, related to the specialty pharmaceutical customers.

+ References

No definition available.

+ Details

Name:	incy_SchedulesOfConcentrationOfRiskByRiskFactorRelatedToSpecialtyPharmaceuticalCustomersTableTextBlock
Namespace Prefix:	incy_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_RisksAndUncertaintiesAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration